Abbott wins CE mark for sepsis molecular Dx; NICE gives thumbs-down to two new prostate cancer tests; Protagen ropes in $12.4M in financing to develop in vitro diagnostics;

> Abbott Laboratories ($ABT) won a CE mark for its molecular diagnostic platform for blood-related infections. Story

> U.K. cost watchdog NICE issued draft guidance recommending against the use of two new prostate cancer tests. More

> Protagen closed a €10 million ($12.4 million) financing round led by investors such as Qiagen ($QGEN) to support development of its in vitro diagnostic tests. Story

> The FDA cleared a new screening test that predicts a patient's risk of developing coronary heart disease. Statement

> Exact Sciences ($EXAS) is planning to offer 4 million shares in a public offering to fuel commercialization of its noninvasive stool-based test for colorectal cancer. Story

> U.K.-based 14M Genomics snagged £12.5 million ($19.7 million) in equity financing to develop oncology diagnostic services. More

> NanoString Technologies ($NSTG) revealed promising study results for its Prosigna breast cancer diagnostic which showed that use of the test significantly changed oncologists' treatment recommendations. More

> Quidel won FDA approval for its molecular diagnostic test for Bordetella pertussis. Story

> Good Start Genetics, IviGen and IviGen's parent company iGenomix are teaming up to offer reproductive genetic diagnostic products and services to in vitro fertilization specialists and women's health professionals in the U.S. and Canada. More

And Finally… The National Institutes of Health awarded a Rutgers researcher a $640,000 grant to develop a rapid Ebola diagnostic test that is designed to be performed on Cepheid's ($CPHD) GeneXpert platform. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.